<DOC>
	<DOC>NCT01227317</DOC>
	<brief_summary>The purpose of this study is to evaluate the capacity of some novels biomarkers Procalcitonin (PCT), Midregional Proadrenomedullin (MR pro ADM), Midregional pro-atrial natriuretic peptide (MR pro ANP), Copeptin (CT pro arginine vasopressin), Pro endothelin to stratify the risk in severe dyspnea.</brief_summary>
	<brief_title>BIOmarkers of Dyspnea IN Emergency Room</brief_title>
	<detailed_description>In emergency department shortness of breath (SOB)is a common symptom and its cause is not easy to be identified. The risk stratifying remains a challenge, Prognostic value of biomarkers might be helpful.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<criteria>tachypnea &gt; 25 /min or Pa02 &lt; 70 mmHg or SpO2 &lt; 93% diagnosis suspected: CAP, PE,EACOPD, AHF other cause of dyspnea, unreachable on Day 30</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Dyspnea</keyword>
	<keyword>Mortality</keyword>
</DOC>